{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibgzipnmuurmdgacqhr4xb2dgttowk4ebrbgn7gowar5vfwq7ubqy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmzkxrk47l22"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifyg3mk2m7nqk2q7yyl2xcffuqfh63xy542vxske6bpigsrf42q3e"
    },
    "mimeType": "image/jpeg",
    "size": 368133
  },
  "path": "/news/2026-05-teclistamab-remission-relapsed-myeloma-free.html",
  "publishedAt": "2026-05-29T17:00:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international Phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.",
  "title": "Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months"
}